BL 8040

Drug Profile

BL 8040

Alternative Names: 4F-Benzoyl-TN14003; BKT-140; BL-8040; TF-14016; TN-14003

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyoto University
  • Developer Biokine Therapeutics; BioLineRx; Genentech; Merck AG; University of Texas M. D. Anderson Cancer Center
  • Class Antianaemics; Antineoplastics; Peptides
  • Mechanism of Action Apoptosis stimulants; Cell movement activators; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Stem cell mobilisation
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Pancreatic cancer; Stem cell mobilisation
  • Phase I/II Aplastic anaemia; Gastric cancer; Multiple myeloma; Myelodysplastic syndromes
  • Preclinical Non-small cell lung cancer
  • No development reported Autoimmune disorders; Chronic myeloid leukaemia; Thrombocytopenia

Most Recent Events

  • 21 Nov 2017 BioLineRx and Genentech plan a phase Ib/II trial for Non-small cell lung cancer (Combination therapy) by early 2018
  • 21 Nov 2017 BioLineRx completes enrolment in the phase II COMBAT trial in Pancreatic cancer (Combination therapy, Metastatic disease) in Israel and USA (SC) before November 2017
  • 21 Nov 2017 BioLineRx plans the registrational phase III GENESIS trial for Stem-cell mobilisation for autologous bone-marrow transplantation by the end of 2017 (NCT03246529)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top